{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:36:49Z","timestamp":1783341409031,"version":"3.54.6"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,9,12]],"date-time":"2014-09-12T00:00:00Z","timestamp":1410480000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s12185-014-1666-z","type":"journal-article","created":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T08:48:23Z","timestamp":1410425303000},"page":"611-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia"],"prefix":"10.1007","volume":"100","author":[{"given":"Mariko","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Tomimasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyasu","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaburo","family":"Sueoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,12]]},"reference":[{"key":"1666_CR1","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1586\/14737140.2013.859074","volume":"13","author":"EJ Jabbour","year":"2013","unstructured":"Jabbour EJ, Cortes JE, Kantarjian HM. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther. 2013;13:1433\u201352.","journal-title":"Expert Rev Anticancer Ther."},{"key":"1666_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10147-013-0641-7","volume":"19","author":"S Kimura","year":"2014","unstructured":"Kimura S, Ando T, Kojima K. Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol. 2014;19:3\u20139.","journal-title":"Int J Clin Oncol."},{"key":"1666_CR3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12185-012-1043-8","volume":"95","author":"PC Trask","year":"2012","unstructured":"Trask PC, Mitra D, Iyer S, Candrilli SD, Kaye JA. Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol. 2012;95:535\u201344.","journal-title":"Int J Hematol."},{"key":"1666_CR4","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.4187\/respcare.01125","volume":"56","author":"A Khan","year":"2011","unstructured":"Khan A, Agarwal R. Pulmonary alveolar proteinosis. Respir Care. 2011;56:1016\u201328.","journal-title":"Respir Care."},{"key":"1666_CR5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clim.2010.02.017","volume":"135","author":"B Carey","year":"2010","unstructured":"Carey B, Trapnell BC. The molecular basis of pulmonary alveolar proteinosis. Clin Immunol. 2010;135:223\u201335.","journal-title":"Clin Immunol."},{"key":"1666_CR6","first-page":"146","volume":"33","author":"K Ohmachi","year":"2008","unstructured":"Ohmachi K, Ogiya D, Morita F, Kojima M, Tsuboi K, Tazume K, et al. Secondary pulmonary alveolar proteinosis in a patient with chronic myeloid leukemia in the accelerated phase. Tokai J Exp Clin Med. 2008;33:146\u20139.","journal-title":"Tokai J Exp Clin Med."},{"key":"1666_CR7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0002-9343(03)00445-5","volume":"115","author":"U Wagner","year":"2003","unstructured":"Wagner U, Staats P, Moll R, Feek U, Vogelmeier C, Groneberg DA. Imatinib-associated pulmonary alveolar proteinosis. Am J Med. 2003;115:674.","journal-title":"Am J Med."},{"key":"1666_CR8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/RTI.0b013e3181930ed6","volume":"24","author":"JH Chung","year":"2009","unstructured":"Chung JH, Pipavath SJ, Myerson DH, Godwin D. Secondary pulmonary alveolar proteinosis: A confusing and potentially serious complication of hematological malignancy. J Thorac Imaging. 2009;24:115\u20138.","journal-title":"J Thorac Imaging."},{"key":"1666_CR9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.autrev.2014.01.046","volume":"13","author":"I Ben-Dov","year":"2014","unstructured":"Ben-Dov I, Segel MJ. Autoimmune pulmonary alveolar proteinosis: clinical course and diagnostic criteria. Autoimmun Rev. 2014;13:513\u20137.","journal-title":"Autoimmun Rev."},{"key":"1666_CR10","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1183\/09031936.00160908","volume":"33","author":"R Borie","year":"2009","unstructured":"Borie R, Debray MP, Laine C, Aubier M, Crestani B. Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur Respir J. 2009;33:1503\u20136.","journal-title":"Eur Respir J."},{"issue":"1","key":"1666_CR11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10245330600937929","volume":"12","author":"E Al Sobhi","year":"2007","unstructured":"Al Sobhi E, Zahrani Z, Zevallos E, Zuraiki A. Imatinib-induced immune hepatitis: case report and literature review. Hematology. 2007;12(1):49\u201353 PubMed PMID: 17364993.","journal-title":"Hematology."},{"key":"1666_CR12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0140-6736(08)61295-7","volume":"372","author":"D Rea","year":"2008","unstructured":"Rea D, Bergeron A, Fieschi C, Bengoufa D, Oksenhendler E, Dombret H. Dasatinib-induced lupus. Lancet. 2008;372:713\u20134.","journal-title":"Lancet."},{"key":"1666_CR13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1440-1711.2004.01296.x","volume":"83","author":"AL Dewar","year":"2005","unstructured":"Dewar AL, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol Cell Biol. 2005;83:48\u201356 PubMed PMID: 15661041.","journal-title":"Immunol Cell Biol."},{"key":"1666_CR14","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1158\/0008-5472.CAN-12-3425","volume":"73","author":"S Bunda","year":"2013","unstructured":"Bunda S, Kang MW, Sybingco SS, Weng J, Favre H, Shin DH, et al. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia. Cancer Res. 2013;73:2540\u201350.","journal-title":"Cancer Res."},{"key":"1666_CR15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","volume":"13","author":"EK Greuber","year":"2013","unstructured":"Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer. 2013;13:559\u201371.","journal-title":"Nat Rev Cancer."},{"key":"1666_CR16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12185-013-1474-x","volume":"99","author":"L Harbaum","year":"2014","unstructured":"Harbaum L, Marx A, Goekkurt E, Schafhausen P, Atanackovic D. Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity. Int J Hematol. 2014;99:91\u20134.","journal-title":"Int J Hematol."},{"key":"1666_CR17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12185-012-1222-7","volume":"97","author":"Y Ito","year":"2013","unstructured":"Ito Y, Miyamoto T, Chong Y, Maki T, Akashi K, Kamimura T. Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin. Int J Hematol. 2013;97:135\u20138.","journal-title":"Int J Hematol."},{"key":"1666_CR18","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2169\/internalmedicine.33.710","volume":"33","author":"K Ito","year":"1994","unstructured":"Ito K, Iwabe K, Okai T, Kouda S, Tadokoro M, Isiko T. Rapidly progressive pulmonary alveolar proteinosis in a patient with chronic myelogenous leukemia. Intern Med. 1994;33:710\u20133.","journal-title":"Intern Med."},{"key":"1666_CR19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/hon.2020","volume":"31","author":"R Latagliata","year":"2013","unstructured":"Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, et al. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol. 2013;31:363\u20139.","journal-title":"Hematol Oncol."},{"key":"1666_CR20","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O\u2019brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908\u201314.","journal-title":"J Clin Oncol."},{"key":"1666_CR21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11523-009-0110-4","volume":"4","author":"K Kelly","year":"2009","unstructured":"Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol. 2009;4:99\u2013105.","journal-title":"Target Oncol."},{"key":"1666_CR22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1164\/rccm.201001-0008OC","volume":"182","author":"T Sakagami","year":"2010","unstructured":"Sakagami T, Beck D, Uchida K, Suzuki T, Carey BC, Nakata K, et al. Patient-derived granulocyte\/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med. 2010;182:49\u201361.","journal-title":"Am J Respir Crit Care Med."},{"issue":"2","key":"1666_CR23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1164\/ajrccm.163.2.2003146","volume":"163","author":"JF Seymour","year":"2001","unstructured":"Seymour JF, Presneill JJ, Schoch OD, Downie GH, Moore PE, Doyle IR, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med. 2001;163(2):524\u201331.","journal-title":"Am J Respir Crit Care Med."},{"key":"1666_CR24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1378\/chest.130.1.227","volume":"130","author":"SB Venkateshiah","year":"2006","unstructured":"Venkateshiah SB, Yan TD, Bonfield TL, Thomassen MJ, Meziane M, Czich C, et al. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest. 2006;130:227\u201337.","journal-title":"Chest."},{"key":"1666_CR25","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1164\/rccm.200906-0978OC","volume":"181","author":"R Tazawa","year":"2010","unstructured":"Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, Nasuhara Y, et al. Inhaled granulocyte\/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2010;181:1345\u201354.","journal-title":"Am J Respir Crit Care Med."},{"key":"1666_CR26","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1183\/09031936.00076711","volume":"39","author":"K Ohashi","year":"2012","unstructured":"Ohashi K, Sato A, Takada T, Arai T, Kasahara Y, Hojo M, et al. Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis. Eur Respir J. 2012;39:777\u201380.","journal-title":"Eur Respir J."},{"key":"1666_CR27","first-page":"7","volume":"79","author":"E Balleari","year":"1994","unstructured":"Balleari E, Bason C, Visani G, Gobbi M, Ottaviani E, Ghio R. Serum levels of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in treated patients with chronic myelogenous leukemia in chronic phase. Haematologica. 1994;79:7\u201312.","journal-title":"Haematologica."},{"key":"1666_CR28","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","volume":"109","author":"Y Wang","year":"2007","unstructured":"Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL\u00a0+\u00a0progenitors via JAK-2\/STAT-5 pathway activation. Blood. 2007;109:2147\u201355.","journal-title":"Blood."},{"key":"1666_CR29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1440-1843.2012.02274.x","volume":"18","author":"S Leth","year":"2013","unstructured":"Leth S, Bendstrup E, Vestergaard H, Hilberg O. Autoimmune pulmonary alveolar proteinosis: treatment options in year 2013. Respirology. 2013;18:82\u201391.","journal-title":"Respirology."},{"key":"1666_CR30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.leukres.2007.07.023","volume":"32","author":"M Breccia","year":"2008","unstructured":"Breccia M, Martelli M, Cannella L, Russo E, Finolezzi E, Stefanizzi C, et al. Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma. Leuk Res. 2008;32:353\u20135.","journal-title":"Leuk Res."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1666-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-014-1666-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1666-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:11:21Z","timestamp":1559452281000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-014-1666-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1666"],"URL":"https:\/\/doi.org\/10.1007\/s12185-014-1666-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,12]]}}}